Financial Performance - The company expects a net loss of between 29 million yuan and 42 million yuan for the year 2024, compared to a net loss of 73.72 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 45 million yuan and 64 million yuan, down from a loss of 96.06 million yuan in the previous year[2]. - The basic earnings per share are expected to be a loss between 0.3067 yuan and 0.4442 yuan, compared to a loss of 0.7797 yuan per share last year[2]. Strategic Focus - The company is focusing on its "A+" strategy, with steady progress in operational management, innovation, and reform efforts, particularly in the accelerator and healthcare sectors[4]. - Significant investments are being made in the development and promotion of healthcare, nuclear environmental protection, and silicon photonics businesses, which are currently incurring losses[4]. Market Conditions - The company is experiencing pressure on product prices and gross margins due to industry cycle adjustments and intensified market competition in the new materials business[4]. Asset Management - The company plans to conduct comprehensive asset inspections and impairment tests, with provisions for potential asset impairments[5]. - The preliminary financial data is subject to change, and the final figures will be disclosed in the 2024 annual report[6].

Group 1 - The company 中广核俊尔 (Zhongguang Nuclear Juner) has recently been established with a registered capital of 41.5 million yuan [2] - The legal representative of 中广核俊尔 is 相军 (Xiang Jun) [2] - The business scope of 中广核俊尔 includes manufacturing leather products, plastic products, machinery equipment leasing, import and export of goods, and technology import and export [2] Group 2 - 中广核技 (China General Nuclear Power Corporation) holds 100% ownership of 中广核俊尔 [1]

何祖元先生在任职期间恪尽职守、勤勉尽责，公司及董事会对其在任董事期 间为公司发展做出的贡献表示衷心地感谢。 中广核核技术发展股份有限公司（以下简称"公司"）董事会于 2024 年 12 月 26 日收到非独立董事何祖元先生提交的书面辞职报告，何祖元先生因到龄退 休，申请辞去公司董事及董事会战略委员会委员、董事会薪酬委员会委员职务， 辞职后不再担任公司任何职务。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》和《公司章程》的有关规定，何祖元先生的辞职 不会导致公司董事会成员低于法定最低人数，不影响董事会的正常运作。何祖元 先生的辞职报告自送达公司董事会之日起生效。公司董事会将按法定程序尽快完 成董事的补选工作。截至本公告披露日，其未持有本公司股份。 证券代码：000881 证券简称：中广核技 公告编号：2024-074 特此公告。 中广核核技术发展股份有限公司 关于董事辞职的公告 中广核核技术发展股份有限公司 董事会 2024年12月28日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 ...

Summary of Conference Call on Nuclear Technology Application Industry and Company Insights Company Overview - The company discussed is 中广核技 (CGN Technology), which focuses on the application of nuclear technology, particularly in non-power sectors. It has been tracked for a significant period and is seen as a leader in the nuclear technology application industry [1][19]. Industry Insights - The nuclear technology application industry encompasses various fields, including industrial, agricultural, food, medical health, and public safety. The International Atomic Energy Agency has noted that the breadth of its applications is comparable only to electronics and new technologies [2]. - A significant policy was introduced by the China Atomic Energy Authority in October, outlining a three-year action plan for the high-quality development of the nuclear technology application industry, aiming for a direct economic output of 400 billion yuan by 2026 [3]. Core Business Segments - The company operates in three main business areas: 1. **Electronic Accelerators and Auxiliary Processing**: This is the core business, with a focus on industrial applications and a market share of approximately 70% in China [23]. 2. **New Materials**: The company is transitioning towards high-value-added products, including materials for renewable energy sectors [11]. 3. **Medical Applications**: Significant investments have been made in proton therapy equipment for cancer treatment, with plans for domestic production of advanced medical devices [8][10]. Financial Performance and Projections - The company reported a loss of 700 million yuan last year, with expectations of a smaller loss this year. However, there are projections for a turnaround, with potential profits of around 200 million yuan in the coming years [5][14]. - The company is expected to benefit from the ongoing reforms in state-owned enterprises and the strategic support from its parent company, 中广核集团 (CGN Group) [4][15]. Strategic Initiatives - The company is actively divesting non-core assets, particularly in real estate and unrelated businesses, to streamline operations and focus on its main areas of expertise [5][13]. - There is an emphasis on enhancing production capacity and integrating external acquisitions to bolster growth in the nuclear technology application sector [6][12]. Market Opportunities - The market for proton therapy equipment is projected to be substantial, with estimates suggesting a potential market size of 100 billion yuan if the rollout of necessary facilities accelerates [10][28]. - The company is also exploring opportunities in the isotope supply chain and aims to enhance its role in the nuclear technology application industry through strategic partnerships and investments [25][24]. Conclusion - The company is positioned to leverage its strengths in nuclear technology applications, supported by favorable government policies and a strategic focus on high-value sectors. The anticipated recovery in financial performance and the potential for significant market growth in medical and new materials sectors present promising investment opportunities [16][30].

Investment Rating - Buy rating (first coverage) with a target price of 10.76 RMB, implying a 33% upside from the current price [2][16] Core Views - The company is a rare player in the non-power nuclear technology application sector, with strong backing from its parent company, CGN, and is expected to benefit from state-owned enterprise reforms and industry policy support [2][11] - The non-power nuclear technology industry in China is poised for rapid growth, driven by top-level policy design and domestic substitution opportunities, particularly in high-end applications like medical and environmental protection [2][11] - The company has a diversified layout in nuclear technology applications, with significant progress in electronic accelerators, modified materials, and nuclear medical businesses, supported by technological innovation and market-oriented strategies [2][11] Company Overview - The company is a leading platform for non-power nuclear technology applications under CGN, with a focus on electronic accelerators, modified materials, and nuclear medical businesses [2][10] - It has a strong market position in electronic accelerators, with a domestic market share leader in industrial electronic accelerators and a design capacity of 90 units/year [2] - The modified materials business contributes nearly 80% of revenue, with a leading position in optical communication materials and significant potential in nuclear and renewable energy sectors [2] - The nuclear medical business is a key growth driver, with the first domestic commercial multi-room proton therapy equipment production base starting operations in November 2024 [2] Industry Overview - Non-power nuclear technology plays a crucial role in national defense and the economy, with the government issuing the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" to promote domestic substitution and industry growth [2][11] - The industry is expected to see rapid development in high-end applications such as medical, environmental protection, and nuclear agriculture, with domestic companies likely to benefit from policy support and technological advancements [2][11] Financial Forecast - Revenue is projected to grow from 7 billion RMB in 2024 to 9.9 billion RMB in 2026, with net profit turning positive in 2025 and reaching 409 million RMB in 2026 [2][16] - The company is expected to achieve a compound annual growth rate (CAGR) of 18% in revenue from 2024 to 2026, driven by its diversified business layout and policy support [2][16] Key Growth Drivers - Expansion of electronic accelerator applications in new fields such as environmental protection and EB curing [2][92] - Growth in high-value-added modified materials, particularly in nuclear and renewable energy sectors [2][11] - Progress in nuclear medical equipment commercialization and isotope production [2][14] Competitive Advantages - Strong technological and market advantages in electronic accelerators, with products exported to 12 countries [2][95] - Leading position in modified materials, with a comprehensive product portfolio and extensive customer base [2][100] - Strategic focus on high-end nuclear medical equipment and isotope production, supported by CGN's resources [2][11]

深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 2803-04 室 邮编：518048 电话：(86-755) 2939-5288 传真：(86-755) 2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于中广核核技术发展股份有限公司 2024 年第五次临时股东会的法律意见书 致：中广核核技术发展股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）受中广核核技术发展股份 有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2024 年第五次临时股东 会（以下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等中国现行法律、法规和规范性文件（以下简称"中国法 律、法规"，为本法律意见书之目的，"中国"不包括香港特别行政区、澳门特别行政 区及台湾）以及现行《中广核核技术发展股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、 召 ...

证券代码：000881 证券简称：中广核技 公告编号：2024-073 中广核核技术发展股份有限公司 2024 年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： （1）现场会议召开日期、时间：2024年12月6日（星期五）下午2:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2024年12月6日上午9:15至9:25、9:30至11:30、下午1:00至3:00；通过深 圳证券交易所互联网投票系统投票的具体时间为2024年12月6日上午9:15至下午 3:00期间的任意时间。 4.召集人：公司董事会。 5.主持人：公司董事长李勇先生因工作原因不能出席会议，公司半数以上董事 推举董事、总经理盛国福先生主持本次股东会。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 ...

证券代码：000881 证券简称：中广核技 公告编号：2024-071 中广核核技术发展股份有限公司 第十届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 经出席会议的董事审议和表决，本次会议形成以下决议： 1.审议通过《关于审批公司与甘露医药设立合资公司的议案》 为助力公司辐照业务转型升级，公司拟与西藏甘露医药科技有限责任公司 （以下简称"甘露医药"）合作建设高原综合灭菌中心。 经审议，董事会同意公司与甘露医药在拉萨合资设立西藏中广核甘露科技有 限责任公司（暂定名，最终以工商登记为准），公司注册资本不超过 4,082 万元， 其中中广核技出资不超过 2,082 万元，出资比例 51%。 一、董事会会议召开情况 1.中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）第 十届董事会第二十二次会议（以下简称"本次会议"）通知于 2024 年 12 月 2 日 以电子邮件形式发出。 2.本次会议于 2024 年 12 月 5 日 14:30 在深圳市福田区深南大道 2002 号中广 核大厦北楼 19 层中广核技 881 会 ...

中德证券有限责任公司关于中广核核技术发展股份有限公司 募集资金投资项目结项并将节余募集资金永久补充流动资 金的核查意见 中德证券有限责任公司（以下简称"中德证券"、"独立财务顾问"）作为中 广核核技术发展股份有限公司（以下简称"中广核技"、"大连国际"或"公司"） 发行股份购买资产并募集配套资金暨关联交易的独立财务顾问，根据《深圳证券 交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》等有关规定，对中广核技发行股份购买资产并募集配套资金投资 项目结项并将节余募集资金永久补充流动资金的情况进行了审慎核查，核查情况 如下： 一、募集资金基本情况 1、基本情况 经中国证券监督管理委员会《关于核准中国大连国际合作（集团）股份有限 公司向中广核核技术应用有限公司等发行股份购买资产并募集配套资金的批复》 （证监许可[2016]2412 号）核准，公司非公开发行人民币普通股（A 股） 267,686,421 股，每股面值 1 元，实际发行价格每股 10.46 元，共募集人民币 2,799,999,963.66 ...